Ranbaxy swings back to profit
25 Feb 2010
Ranbaxy Laboratories Limited, among the top 10 generic manufacturers in the world, today reported a net profit after tax of Rs488.23 crore in the quarter ended 31 December 2009 against a net loss of Rs819 crore in the comparable quarter of the previous year (ended 31 December 2008).
Total income of the company increased to Rs1,708.88 crore during the quarter from Rs1,080 crore in the quarter ended 31 December 2008.
Ranbaxy, now part of Japan's Daiichi Sankyo group, posted a net profit after tax of Rs571.98 crore during the year ended 31 December 2009 against a net loss of Rs1,044.80 crore in the previous year. Total income of the company increased to Rs5,059.15 crore from Rs4,680.81 crore in the previous year (ended 31 December 2008).
Ranbaxy Laboratories, based in Gurgaon, reported global sales of Rs7,344.1 crore ($1.519 billion) during the year ended 31 December 2009 against Rs7,255.5 crore (1.667 billion) in the previous year.
Profit before tax during the year was lower at Rs1,009.8 crore ($209 million) - a margin of 14 per cent to sales - against Rs1,500 crore ($320 million) in the year ended 31 December 2008.
Profit after tax during the year ended 31 December 2009 stood at Rs310 crore ($64 million) - a margin of 4 per cent to sales - against Rs934 crore ($198 million) in the previous year.